PBYI - Puma Biotechnology Inc Stock Price, Fair Value and News

5.36USD+0.09 (+1.71%)Market Closed

Market Summary

USD5.36+0.09

Market Closed

1.71%

PBYI Stock Price

View Fullscreen

PBYI RSI Chart

PBYI Valuation

Market Cap

258.4M

Price/Earnings (Trailing)

11.97

Price/Sales (Trailing)

1.1

EV/EBITDA

5.04

Price/Free Cashflow

9.62

PBYI Price/Sales (Trailing)

PBYI Profitability

Operating Margin

73.51%

EBT Margin

9.62%

Return on Equity

40.4%

Return on Assets

9.37%

Free Cashflow Yield

10.4%

PBYI Fundamentals

PBYI Revenue

Revenue (TTM)

235.6M

Rev. Growth (Yr)

9.9%

Rev. Growth (Qtr)

28.62%

PBYI Earnings

Earnings (TTM)

21.6M

Earnings Growth (Yr)

318.84%

Earnings Growth (Qtr)

111.66%

Breaking Down PBYI Revenue

Last 7 days

-4.8%

Last 30 days

7.2%

Last 90 days

-1.5%

Trailing 12 Months

77.5%

How does PBYI drawdown profile look like?

PBYI Financial Health

Current Ratio

1.57

Debt/Equity

1.23

Debt/Cashflow

0.41

PBYI Investor Care

Shares Dilution (1Y)

3.36%

Diluted EPS (TTM)

0.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	235.1M	230.1M	229.1M	235.6M
2022	200.7M	206.9M	217.7M	228.0M
2021	272.1M	254.9M	250.4M	253.2M
2020	224.4M	241.1M	235.5M	225.1M
2019	283.5M	286.7M	280.4M	272.3M
2018	86.3M	145.0M	201.5M	251.0M
2017	0	0	0	27.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Puma Biotechnology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	auerbach alan h	acquired	-	-	6,577	president and ceo
Feb 12, 2024	hunt douglas m	acquired	-	-	37,894	see remarks
Feb 12, 2024	ludwig jeffrey jerome	acquired	-	-	27,067	chief commercial officer
Feb 12, 2024	wong alvin f	acquired	-	-	43,307	chief scientific officer
Feb 12, 2024	auerbach alan h	acquired	-	-	160,796	president and ceo
Feb 12, 2024	nougues maximo f	acquired	-	-	43,307	chief financial officer
Jan 03, 2024	nougues maximo f	sold	-70,347	4.4859	-15,682	chief financial officer
Jan 03, 2024	hunt douglas m	sold	-37,493	4.4859	-8,358	see remarks
Jan 03, 2024	wong alvin f	sold	-34,689	4.4859	-7,733	chief scientific officer
Jan 03, 2024	ludwig jeffrey jerome	sold	-58,119	4.4859	-12,956	chief commercial officer

Which funds bought or sold PBYI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	0.79	6,541,620	16,463,000	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	175	782,871	1,004,170	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-38,000	-	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	reduced	-6.18	401,000	1,136,000	0.10%
Feb 15, 2024	BARCLAYS PLC	reduced	-10.17	25,000	75,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	595,821	595,821	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	448	492,624	553,958	-%
Feb 14, 2024	TWO SIGMA ADVISERS, LP	added	9.62	549,910	1,233,180	-%
Feb 14, 2024	Prospera Financial Services Inc	added	16.54	296,946	620,130	0.02%
Feb 14, 2024	BOOTHBAY FUND MANAGEMENT, LLC	new	-	77,485	77,485	-%

Are Funds Buying or Selling PBYI?

Are funds buying PBYI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PBYI

No. of Funds

Unveiling Puma Biotechnology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 29, 2024	frazier life sciences public fund, l.p.	2.7%	1,295,100	SC 13G
Feb 14, 2024	camber capital management lp	5.90%	2,013	SC 13G/A
Feb 13, 2024	vanguard group inc	7.99%	3,802,081	SC 13G/A
Feb 06, 2024	acorn bioventures, l.p.	2.6%	1,232,490	SC 13G/A
Jan 30, 2024	millennium management llc	6.0%	2,843,239	SC 13G/A
Sep 01, 2023	acorn bioventures, l.p.	2.4%	1,150,774	SC 13G
Feb 14, 2023	camber capital management lp	9.28%	2,013	SC 13G/A
Feb 09, 2023	vanguard group inc	7.86%	3,588,922	SC 13G/A
Feb 07, 2023	goldman sachs group inc	0.9%	396,136	SC 13G/A
Jan 19, 2023	millennium management llc	5.8%	2,676,913	SC 13G/A

Recent SEC filings of Puma Biotechnology Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	SC 13G	Major Ownership Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading

Peers (Alternatives to Puma Biotechnology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Puma Biotechnology Inc News

Latest updates

Puma Biotechnology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	28.6%	72,178,000	56,116,000	54,568,000	52,775,000	65,675,000	57,102,000	59,518,000	45,736,000	55,357,000	46,245,000	53,384,000	98,169,000	52,557,000	50,754,000	70,582,000	51,217,000	62,922,000	56,352,000	53,919,000	99,067,000	71,079,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	11,969,000	29,557,000	10,940,000	9,943,000	9,415,000	9,076,000	10,142,000	9,371,000	9,317,000	7,985,000	-
Costs and Expenses	20.7%	57,380,000	47,531,000	49,676,000	48,410,000	55,659,000	54,709,000	47,460,000	46,483,000	48,575,500	55,199,000	70,017,000	78,023,000	-	62,885,000	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	70,017,000	78,023,000	63,706,000	62,885,000	63,453,000	65,468,000	71,587,000	70,800,000	79,699,000	89,219,000	89,615,500
S&GA Expenses	-11.5%	20,184,000	22,801,000	24,462,000	22,486,000	25,039,000	23,961,000	20,576,000	20,402,000	22,512,000	26,084,000	39,410,000	28,238,000	28,606,000	29,598,000	29,347,000	30,937,000	31,204,000	31,402,000	33,527,000	45,506,000	40,932,000
R&D Expenses	-	-	-	-	-	-	-	11,966,000	15,237,000	14,168,000	18,836,000	18,638,000	20,228,000	24,160,000	23,344,000	24,691,000	25,455,000	30,241,000	30,027,000	36,855,000	35,728,000	38,324,500
EBITDA Margin	59.9%	0.20	0.13	0.09	0.11	0.09	0.14	-0.06	-0.13	-0.02	-0.09	-0.03	0.00	-	-	-	-	-	-	-	-	-
Interest Expenses	0.4%	3,354,000	3,339,000	3,325,000	3,312,000	3,279,000	2,947,000	2,702,000	2,664,000	2,718,000	3,121,000	3,518,000	3,450,000	3,567,000	3,627,000	3,784,000	3,068,000	3,076,000	3,052,000	4,448,000	4,443,000	3,820,000
Income Taxes	151.6%	536,000	213,000	187,000	147,000	294,000	67,000	57,000	37,000	211,500	37,000	38,000	38,000	207,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	113.1%	12,804,000	6,009,000	2,313,000	1,548,000	-5,312,000	-293,000	9,428,000	-3,366,000	4,385,500	-44,635,000	-5,068,000	16,566,000	-14,787,000	-31,463,000	3,395,000	-16,933,000	-	-	-	-	-
EBT Margin	383.7%	0.10	0.02	-0.01	0.02	0.00	0.05	-0.17	-0.24	-0.11	-0.19	-0.14	-0.10	-	-	-	-	-	-	-	-	-
Net Income	111.7%	12,268,000	5,796,000	2,126,000	1,401,000	-5,606,000	-360,000	9,371,000	-3,403,000	4,174,000	-44,672,000	-5,106,000	16,528,000	-14,994,000	-31,463,000	3,395,000	-16,933,000	-11,199,000	-16,885,000	-37,424,000	-10,087,000	-30,694,000
Net Income Margin	464.8%	0.09	0.02	-0.01	0.02	0.00	0.04	-0.17	-0.24	-0.11	-0.19	-0.14	-0.10	-	-	-	-	-	-	-	-	-
Free Cashflow	-1.8%	10,401,000	10,588,000	3,339,000	2,600,000	7,683,000	17,259,000	-13,874,000	-26,895,000	-5,435,000	10,475,000	-97,000	15,638,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	13.2%	231	204	200	196	222	199	194	201	227	226	260	259	244	262	264	226	235	232	240	331	259
Current Assets	24.6%	156	125	119	112	134	122	114	118	140	137	168	164	146	160	159	159	166	151	158	256	203
Cash Equivalents	3.4%	85.00	82.00	60.00	61.00	76.00	78.00	53.00	64.00	63.00	64.00	90.00	96.00	85.00	90.00	91.00	83.00	60.00	59.00	27.00	49.00	108
Inventory	24.7%	7.00	6.00	8.00	4.00	5.00	5.00	7.00	7.00	7.00	7.00	8.00	8.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Net PPE	-5.7%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00
Liabilities	7.4%	177	165	170	170	200	177	174	194	229	237	231	242	250	262	240	216	217	215	218	288	225
Current Liabilities	47.5%	99.00	67.00	60.00	48.00	77.00	60.00	57.00	75.00	110	116	138	140	114	118	95.00	90.00	91.00	88.00	92.00	101	67.00
Long Term Debt	-14.3%	66.00	77.00	88.00	99.00	98.00	98.00	98.00	97.00	97.00	97.00	69.00	76.00	84.00	92.00	97.00	96.00	95.00	94.00	93.00	153	152
LT Debt, Current	50.0%	34.00	23.00	11.00	-	-	-	-	-	-	-	31.00	23.00	14.00	6.00	-	-	-	-	-	-	-
LT Debt, Non Current	-14.3%	66.00	77.00	88.00	99.00	98.00	98.00	98.00	97.00	97.00	97.00	69.00	76.00	84.00	92.00	-	-	95.00	-	-	-	-
Shareholder's Equity	37.9%	53.00	39.00	30.00	26.00	22.00	22.00	20.00	7.00	-2.45	-	29.00	16.00	-5.95	-	23.00	9.00	17.00	17.00	22.00	43.00	34.00
Retained Earnings	0.9%	-1,345	-1,357	-1,363	-1,365	-1,366	-1,361	-1,360	-1,370	-1,366	-1,370	-1,326	-1,321	-1,337	-1,322	-1,291	-1,294	-1,277	-1,266	-1,249	-1,212	-1,202
Additional Paid-In Capital	0.2%	1,399	1,396	1,394	1,391	1,388	1,383	1,381	1,377	1,364	1,360	1,356	1,338	1,332	1,322	1,315	1,304	1,295	1,283	1,271	1,256	1,236
Shares Outstanding	0.2%	48.00	48.00	47.00	47.00	46.00	46.00	44.00	42.00	41.00	41.00	40.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	141	-	-	-	112	-	-	-	374	-	-	-	413	-	-	-	428	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-2.8%	10,400	10,700	3,257	2,643	7,683	17,259	-13,874	-26,895	-5,435	10,498	-74.00	15,661	-5,635	1,720	16,228	-11,540	1,566	-7,307	44,247	-16,130	7,047
Share Based Compensation	-4.4%	2,432	2,545	2,432	2,838	2,628	2,830	3,220	3,148	4,252	4,282	18,239	5,860	9,473	7,565	10,630	8,907	11,536	12,213	15,440	18,138	18,596
Cashflow From Investing	-173.1%	-8,170	11,178	-4,683	-17,450	-11,873	7,998	1,997	8,982	4,621	-4,470	-5,731	-5,301	10,823	-2,578	-9,219	34,377	-432	38,972	11,206	-44,583	2,582
Cashflow From Financing	-	-	-	-	-	2,431	-53.00	-	9,845	-2.00	-31,929	-	-	-9,977	43.00	-	-	-1.00	76.00	-68,224	1,082	30,492

PBYI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 235,637	$ 228,031	$ 253,155
Operating costs and expenses:
Cost of sales	62,682	55,093	63,701
Selling, general and administrative	89,933	89,978	116,294
Research and development	50,382	52,240	71,870
In-process research and development expenses	0	7,000	0
Total operating costs and expenses	202,997	204,311	251,865
Income from operations	32,640	23,720	1,290
Other income (expenses):
Interest income	2,605	813	160
Interest expense	(13,330)	(11,592)	(12,807)
Legal verdict expense	0	(12,456)	(9,591)
Loss on debt extinguishment	0	0	(8,146)
Other income (expense)	759	(28)	292
Total other expenses, net	(9,966)	(23,263)	(30,092)
Net income (loss) before income taxes	22,674	457	(28,802)
Income tax expense	(1,083)	(455)	(324)
Net income (loss)	$ 21,591	$ 2	$ (29,126)
Net income (loss) per share of common stock—basic (in dollars per share)	$ 0.46	$ 0	$ (0.72)
Net income (loss) per share of common stock—diluted (in dollars per share)	$ 0.45	$ 0	$ (0.72)
Weighted-average shares of common stock outstanding—basic (in shares)	47,134,331	44,674,501	40,638,852
Weighted-average shares of common stock outstanding—diluted (in shares)	47,550,852	44,929,998	40,638,852
Product [Member]
Total revenue	$ 203,107	$ 200,023	$ 189,064
License [Member]
Total revenue	0	0	51,750
Royalty [Member]
Total revenue	$ 32,530	$ 28,008	$ 12,341

PBYI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 84,585	$ 76,201
Marketable securities	11,354	4,873
Accounts receivable, net of allowance for credit loss of $881 and $0	47,837	40,350
Inventory, net	7,080	4,526
Prepaid expenses, current	4,417	5,902
Other assets, current	912	2,429
Total current assets	156,185	134,281
Lease right-of-use assets, net	7,792	11,362
Property and equipment, net	855	1,146
Intangible assets, net	60,871	70,610
Restricted cash, long-term	2,091	2,591
Prepaid expenses and other, long-term	2,734	2,069
Total assets	230,528	222,059
Current liabilities:
Accounts payable	6,889	6,440
Accrued expenses, current	52,721	53,034
Accrued in-licensed rights, current	0	12,500
Post-marketing commitment liability, current	975	1,370
Lease liabilities, current	4,800	4,140
Current portion of long-term debt	33,997	0
Total current liabilities	99,382	77,484
Accrued expenses, long-term	121	7,391
Lease liabilities, long-term	7,034	11,834
Post-marketing commitment liability, long-term	4,890	5,435
Total long-term debt, net	65,659	98,307
Total liabilities	177,086	200,451
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock - $.0001 par value per share; 100,000,000 shares authorized; 47,646,787 shares issued and outstanding at December 31, 2023 and 46,345,660 issued and outstanding at December 31, 2022	5	5
Additional paid-in capital	1,398,605	1,388,358
Accumulated other comprehensive loss	(4)	0
Accumulated deficit	(1,345,164)	(1,366,755)
Total stockholders' equity	53,442	21,608
Total liabilities and stockholders' equity	$ 230,528	$ 222,059

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

CEO	Mr. Alan H. Auerbach
WEBSITE	pumabiotechnology.com
INDUSTRY	Biotechnology
EMPLOYEES	192

Puma Biotechnology Inc Frequently Asked Questions

What is the ticker symbol for Puma Biotechnology Inc? What does PBYI stand for in stocks?

PBYI is the stock ticker symbol of Puma Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Puma Biotechnology Inc (PBYI)?

As of Mon Apr 15 2024, market cap of Puma Biotechnology Inc is 258.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PBYI stock?

You can check PBYI's fair value in chart for subscribers.

What is the fair value of PBYI stock?

You can check PBYI's fair value in chart for subscribers. The fair value of Puma Biotechnology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Puma Biotechnology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PBYI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Puma Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether PBYI is over valued or under valued. Whether Puma Biotechnology Inc is cheap or expensive depends on the assumptions which impact Puma Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PBYI.

What is Puma Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, PBYI's PE ratio (Price to Earnings) is 11.97 and Price to Sales (PS) ratio is 1.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBYI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Puma Biotechnology Inc's stock?

In the past 10 years, Puma Biotechnology Inc has provided -0.23 (multiply by 100 for percentage) rate of return.